The objective of this protocol is to use a case-control paradigm to compare the responseto an intravenous administration of kisspeptin in individuals with and withoutpost-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.This study will utilize the technique of frequent blood sampling (q10 minutes) to providedetailed neuroendocrine characterization of endogenous LH secretion before and afterkisspeptin administration. This frequency of blood sampling is required to define thefeatures of LH pulses.
Delivery of Interventions:
- 1-2 hours of q10 minute blood sampling
- Administration of a single kisspeptin bolus in a dosing range of 0.313 - 13.19 μg/kg
Drug: Kisspeptin 112-121
Single bolus of kisspeptin
Other Name: Metastin 45-54
Inclusion Criteria
- Female (ages 18-45 years) or Male (ages 18-60 years)
- Normal blood pressure (systolic BP < 140 mm Hg, diastolic < 90 mm Hg)
- Hemoglobin no less than 0.5 g/dL below the lower limit of the sex specific reference
range
- No current or recent use of a medication (including hormonal replacement) that, in
the opinion of a study investigator, can modulate the reproductive axis or willing
to complete an appropriate washout for that particular medication and its method of
administration
- For women, negative serum hCG pregnancy test
- For cases, diagnosis of post-covid-19 syndrome
- For controls, history of prior covid infection but no diagnosis of post-covid-19
syndrome
Exclusion Criteria
- Any condition (medical, mental, or behavioral) that, in the opinion of a study
investigator, would likely interfere with participation in/completion of the
protocol
- Excessive alcohol consumption (>10 drinks/week)
- Active use of illicit drugs
- For women,
- Pregnant
- Trying to become pregnant during protocol participation
- Breast feeding
- History of any of the following: bilateral oophorectomy (ovaries were removed),
breast cancer, thromboembolic disease, coronary artery disease, stroke,
thrombophilic disorders, or undiagnosed abnormal genital bleeding
Massachusetts General Hospital
Boston, Massachusetts, United States
Investigator: Study Coordinator
Contact: 617-643-2308
MGHKisspeptinResearch@partners.org
Study Coordinator
617-643-2308
MGHKisspeptinResearch@partners.org
Not Provided